COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.

Epidemiolgia (Basel, Switzerland) Pub Date : 2025-06-04 DOI:10.3390/epidemiologia6020026

Réka Bodea, Toader Septimiu Voidăzan, Lorand Iozsef Ferencz, Zoltán Ábrám

{"title":"COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.","authors":"Réka Bodea, Toader Septimiu Voidăzan, Lorand Iozsef Ferencz, Zoltán Ábrám","doi":"10.3390/epidemiologia6020026","DOIUrl":null,"url":null,"abstract":"Background: Frequency indicators are used by epidemiologists to facilitate public health professionals in estimating the impact of diseases. As of April 2022, Romania had reported 2.8 million confirmed COVID-19 cases to the World Health Organization, equating to a prevalence rate of 13.94%. A more accurate method for assessing the cumulative number of cases is the use of seroprevalence studies. This study retrospectively evaluates infection trends in Romania to enhance understanding of the virus's spread and may support future comparative analyses of public health responses and community-level immunity.Methods: We analyzed 51,533 qualitative test results for high-affinity IgG antibodies targeting the SARS-CoV-2 nucleocapsid protein.Results: The largest proportion of tested individuals (59.4%) was aged 18-49 years. Among all serological tests, 18,980 were positive, corresponding to an adjusted seroprevalence rate of 40%.Conclusions: During the second year of the pandemic, seropositivity rates were highest among young adults, particularly in the western regions, and lowest among children and adolescents. These findings point out variations in exposure across age groups and geographic areas.","PeriodicalId":72944,"journal":{"name":"Epidemiolgia (Basel, Switzerland)","volume":"6 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192444/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiolgia (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/epidemiologia6020026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Frequency indicators are used by epidemiologists to facilitate public health professionals in estimating the impact of diseases. As of April 2022, Romania had reported 2.8 million confirmed COVID-19 cases to the World Health Organization, equating to a prevalence rate of 13.94%. A more accurate method for assessing the cumulative number of cases is the use of seroprevalence studies. This study retrospectively evaluates infection trends in Romania to enhance understanding of the virus's spread and may support future comparative analyses of public health responses and community-level immunity.

Methods: We analyzed 51,533 qualitative test results for high-affinity IgG antibodies targeting the SARS-CoV-2 nucleocapsid protein.

Results: The largest proportion of tested individuals (59.4%) was aged 18-49 years. Among all serological tests, 18,980 were positive, corresponding to an adjusted seroprevalence rate of 40%.

Conclusions: During the second year of the pandemic, seropositivity rates were highest among young adults, particularly in the western regions, and lowest among children and adolescents. These findings point out variations in exposure across age groups and geographic areas.

查看原文本刊更多论文

罗马尼亚COVID-19血清阳性率：来自全国抗体研究的见解

背景：频率指标被流行病学家用来帮助公共卫生专业人员估计疾病的影响。截至2022年4月，罗马尼亚向世界卫生组织报告了280万例新冠肺炎确诊病例，患病率为13.94%。评估累积病例数的更准确方法是使用血清患病率研究。本研究回顾性评估了罗马尼亚的感染趋势，以加强对病毒传播的了解，并可能支持未来对公共卫生反应和社区免疫的比较分析。方法：对51533例针对SARS-CoV-2核衣壳蛋白的高亲和力IgG抗体定性检测结果进行分析。结果：18 ~ 49岁人群占比最大（59.4%）；在所有血清学检测中，18,980例阳性，对应于调整后的血清阳性率为40%。结论：在大流行的第二年，血清阳性率在年轻人中最高，特别是在西部地区，儿童和青少年中最低。这些发现指出了不同年龄组和地理区域的暴露差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊